Acute unilateral toxoplasma retinochoroiditis associated with adalimumab, a tumor necrosis factor-α antagonist.
The purpose of this study was to report a case of a patient with unilateral toxoplasma retinochoroiditis while on treatment with adalimumab, an anti-tumor necrosis factor α agent for ulcerative colitis. This is a descriptive case report. In addition to the patient with toxoplasma retinochoroiditis, there is one published report of two patients who developed toxoplasma chorioretinitis while on anti-tumor necrosis factor α therapy for rheumatoid arthritis: one was on adalimumab and methotrexate and the other one was on etanercept and methotrexate. The authors need to be aware of this potentially vision threatening risk with anti-tumor necrosis factor α therapy.